STOCK TITAN

Veradigm - MDRX STOCK NEWS

Welcome to our dedicated page for Veradigm news (Ticker: MDRX), a resource for investors and traders seeking the latest updates and insights on Veradigm stock.

Veradigm Inc. (NASDAQ: MDRX) is a prominent player in the healthcare information technology sector, dedicated to enhancing clinical, financial, and operational results through innovative IT solutions. The company's core business revolves around creating an expansive, open, and connected community of health, which bridges the gaps between people, places, and data. This connectivity is pivotal in empowering caregivers to make informed decisions and deliver superior care, ultimately leading to healthier populations.

Veradigm's comprehensive suite of solutions includes electronic health records (EHR), practice management systems, revenue cycle management, and patient engagement tools. These products are meticulously designed to streamline healthcare operations, improve patient outcomes, and navigate the evolving landscape of healthcare delivery.

Recently, Veradigm has faced significant changes. The company was replaced in the S&P SmallCap 600 by Sprinklr Inc. (NYSE: CXM) and was suspended from the NASDAQ Stock Market effective February 29, 2024, due to non-compliance with NASDAQ listing rules. Despite these challenges, Veradigm continues to innovate and adapt, focusing on delivering value through their cutting-edge technology solutions.

Veradigm's commitment to connectivity extends to their robust partnerships and collaborations. These alliances enhance their ability to offer integrated solutions that meet the dynamic needs of the healthcare sector. Veradigm's financial condition and strategic initiatives reflect their dedication to maintaining leadership in the healthcare IT domain.

For more details and the latest updates on Veradigm Inc., visit their official website or follow their social media channels on Twitter, YouTube, and their blog.

Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) announced that its Board of Directors has approved an amendment to extend its existing Stockholder Rights Plan from February 26, 2025, to August 20, 2025. The amendment updates the exercise price for rights purchase from $50.00 to $32.00.

The extension is driven by ongoing challenges including: the continuing audit of 2022 financial statements, delayed financial reporting due to restatement requirements, and the company's delisted status. The Board noted these factors make tracking share accumulation particularly challenging. The decision was also influenced by a significant stock price decline following the termination of strategic alternatives exploration.

The Rights Plan aims to protect stockholders from potential rapid share accumulations or creeping acquisitions of control without payment of appropriate control premiums. The plan doesn't prevent the company from considering fair offers that benefit stockholders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) has launched seven new disease-specific cardiometabolic Clinical Data Registry datasets to enhance real-world research capabilities. The registries harmonize data from over 80 different electronic health records (EHRs), combining both structured and unstructured data to provide comprehensive insights into disease patterns and treatment outcomes.

The new registry cohorts include specialized datasets for Heart Failure, Atrial Fibrillation, ASCVD, Hypertension, Type 1 Diabetes, Type 2 Diabetes, and Chronic Kidney Disease. The company utilizes Natural Language Processing (NLP) to extract insights from clinical data, particularly focusing on details relevant to life science researchers, public health, and government regulators.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) has achieved top rankings in Black Book Research's 2025 Top-Rated EHR Vendors by Specialty, securing the #1 position for both Ambulatory EHR Family Practice and Primary Care General Practice categories. The recognition follows a comprehensive nine-month survey involving 33,516 respondents across the United States.

The company's EHR solution received exceptional scores, achieving a 9.3 out of 10 (93% client experience rating), particularly excelling in ease of navigation and telehealth integration. The platform serves tens of thousands of providers nationwide and has recently launched Veradigm Ambient Scribe to further enhance provider experience.

Black Book's evaluation highlighted Veradigm's success in adapting to regulatory changes, improving interoperability, enhancing patient engagement, and streamlining practice workflows. The recognition validates Veradigm's commitment to transforming healthcare through innovative solutions that address provider burnout and support the transition to value-based care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.34%
Tags
none
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) announced that Beth Altman resigned from the Board of Directors on January 28, 2025, citing health reasons. Her departure is unrelated to any disagreements with company operations, policies, or practices and does not affect the ongoing restatement of 2022 financial statements.

Following Altman's resignation, who served as Audit Committee Chair since 2020, the Board appointed Greg Garrison as interim Audit Committee Chair. Garrison previously held this position from May 2016 through June 2022. The company is actively seeking stockholder input to identify qualified candidates for Board positions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-31.81%
Tags
management
-
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) announced the integration of new datasets into its Veradigm Network EHR (VNEHR) Data, one of the largest ambulatory electronic health record databases with over 154 million unique patients. The enhancement includes social determinants of health (SDoH) and mortality data, enabling deeper research insights.

The integration addresses the challenge that 80% of critical patient information is typically locked within unstructured data. Using advanced natural language processing (NLP) technology, VNEHR Data now provides research-ready, de-identified data optimized for life science, public health, and academic research.

The new NLP-derived SDoH data includes socioeconomic, environmental, and behavioral factors such as income levels, education, housing stability, and social support. The mortality data addition aims to enhance real-world evidence generation, support post-market surveillance, and improve drug development through better identification of at-risk populations.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.11%
Tags
none
-
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) has launched Veradigm Ambient Scribe, an AI-powered platform designed to reduce healthcare providers' documentation burden. The solution automatically captures and transcribes patient-provider interactions into structured medical notes that integrate with Veradigm EHR. This advancement aims to increase operational efficiency and enhance patient care by allowing clinicians to focus more on patient interactions and less on data entry. The platform, powered by AvodahMed™, joins Veradigm's portfolio of solutions designed to streamline healthcare administrative tasks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.57%
Tags
none
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) announced an enhanced strategic collaboration with Insiteflow to expand Veradigm Payer Insights (VPI) beyond its current EHR footprint. The partnership extends VPI to additional EHR platforms, including Epic, enabling real-time delivery of payer insights directly into healthcare provider workflows.

The collaboration, which began in 2022, integrates care gaps alerts and patient condition recommendations to improve care coordination and clinical outcomes. The system now works across multiple EHR platforms, including Veradigm EHR and Practice Fusion, supporting payer-provider collaboration and advancing value-based care initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.34%
Tags
none
-
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) has announced the complete integration of advanced natural language processing (NLP) into its electronic health record (EHR) dataset. This enhancement allows for deeper clinical insights from unstructured EHR data, combined with structured data to create regulatory-grade, real-world data (RWD) for research purposes.

The Veradigm Network EHR Data is sourced from over 154 million unique patient records, making it one of the most comprehensive ambulatory databases in the United States. It encompasses over five billion distinct patient notes from multiple EHR systems and specialties, collected over a rolling five-year period.

Veradigm's NLP models, developed by clinicians and data scientists, extract important clinical insights into structured data tables. This integration offers researchers valuable insights into therapy decisions, disease progression, and patient outcomes, supporting clinical trials, regulatory submissions, and safety studies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.28%
Tags
none
-
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX) has announced that over 300,000 healthcare providers across the United States are now using its automated medical chart retrieval solution, Veradigm eChart Courier. This milestone highlights the increasing demand for solutions that enhance efficiency, reduce administrative burdens, and facilitate seamless connections between healthcare providers and payers.

The eChart Courier solution automates the medical chart retrieval process, saving time, resources, and expenses for both providers and health plans. It securely delivers medical records via electronic transfer and presents clinical data to health plans in an easily analyzable format.

Tom Langan, Interim CEO, President and Chief Commercial Officer of Veradigm, emphasized the company's commitment to helping healthcare stakeholders control costs and optimize health outcomes through innovative tools like eChart Courier. Keri Straub of Clinix Center for Health praised the solution for improving efficiency, reducing paperwork, enhancing compliance with health plan requirements, and allowing clinical teams to focus more on patient care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.76%
Tags
none
News
Rhea-AI Summary

Veradigm (OTCMKTS: MDRX), a leading healthcare data and technology solutions provider, has been ranked as the top vendor for broad retrospective vendors in KLAS's Risk Adjustment 2024 report. The report highlighted the increasing demand for comprehensive risk adjustment solutions, including both retrospective and prospective capabilities.

Veradigm clients reported strong satisfaction with the company's suite of solutions, making it the most recommended vendor. Clients interviewed by KLAS noted significant outcomes, including increased ROI from retrospective risk adjustment solutions, more reliable submissions, and comprehensive validation processes.

Veradigm's risk adjustment solutions offer a full spectrum of services for health plans, supporting them in achieving operational goals and improving financial performance.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
none

FAQ

What is the current stock price of Veradigm (MDRX)?

The current stock price of Veradigm (MDRX) is $5 as of February 25, 2025.

What is the market cap of Veradigm (MDRX)?

The market cap of Veradigm (MDRX) is approximately 807.3M.

What is Veradigm Inc.?

Veradigm Inc. is a leading provider of healthcare information technology solutions aimed at improving clinical, financial, and operational outcomes.

What type of products does Veradigm offer?

Veradigm offers a range of products including electronic health records (EHR), practice management systems, revenue cycle management, and patient engagement tools.

Why was Veradigm suspended from the NASDAQ Stock Market?

Veradigm was suspended from the NASDAQ Stock Market due to non-compliance with NASDAQ listing rules as of February 29, 2024.

Who replaced Veradigm in the S&P SmallCap 600 index?

Sprinklr Inc. (NYSE: CXM) replaced Veradigm in the S&P SmallCap 600 index effective March 4, 2024.

What distinguishes Veradigm’s healthcare solutions?

Veradigm’s solutions are distinguished by their ability to connect people, places, and data, which empowers caregivers to make better decisions and improve patient care.

Where can I find more information about Veradigm?

More information about Veradigm can be found on their official website, Twitter, YouTube, and their blog.

What is the primary focus of Veradigm’s technology?

Veradigm's technology focuses on creating an open, connected community of health that enhances interoperability and data sharing in healthcare.

How does Veradigm support healthcare providers?

Veradigm supports healthcare providers by offering tools that streamline operations, improve patient outcomes, and facilitate effective decision-making.
Veradigm

OTC:MDRX

MDRX Rankings

MDRX Stock Data

807.30M
105.42M
1.12%
22.77%
Health Information Services
Healthcare
Link
United States
Chicago